Helpful Tips on Self-Administration

With proper training, you can learn to administer Hizentra on your own. However, there may be times you need additional support or guidance when infusing.

When You Have Questions

Remember that your doctor, nurse, and specialty pharmacist are excellent sources of information when you have questions. Make sure to keep their numbers handy. CSL Behring also provides a number of resources to help you:

Hizentra Self Administration Video

Hizentra Self-Administration Video

Watch the Hizentra self-administration video to learn the step-by-step instructions on preparation, proper infusion techniques, and administration. video

Step-by-Step Instructions for Self-Administering Hizentra

Step-by-Step Instructions for Self-Administering Hizentra

Once you've watched the video, use this step-by-step guide for administering.

Troubleshooting Tips

It is important to note that local site reactions are common and expected with subcutaneous therapies because you are infusing something under your skin. In clinical trials, 99.7% were mild or moderate. Many things can cause reactions, including needle length, needle type, product on needle tip, etc. Below are possible issues and helpful strategies to decrease them:

  • Leaking at site: Needle length may need adjustment
  • Extreme needle discomfort: Needle length may need adjustment
  • Blood appears in tubing: May have hit vein. Remove tubing and throw away. Prepare new tubing and begin infusion in a new area.

Call your healthcare professional for more detail on troubleshooting these and other issues not described here.

PI Support From a Personal Point of View

Voice2Voice is a unique program that connects Hizentra patients and caregivers with people who know what it's like to live with PI and have direct experience with Hizentra therapy. Because it's good to know you're not alone.

Important Safety Information
Expand

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
Patient/Caregiver Using Hizentra Administration Guidance
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015